FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008505946> ?p ?o ?g. }

• W2008505946 endingPage "149" @default.
• W2008505946 startingPage "149" @default.
• W2008505946 abstract "In his Jan 6 commentary, Eric Cohen1Cohen EP Renal failure after bone marrow transplantation.Lancet. 2001; 357: 6-7Summary Full Text Full Text PDF PubMed Scopus (60) Google Scholar summarises the causes of acute and chronic renal failure after autologous or allogeneic bone-marrow transplantation (BMT). Specifically, he mentions sepsis due to neutropenia and gastrointestinal exfoliation, hypotension, haemolyticuraemic syndromes, acute tubular necrosis, tumour-lysis syndrome, concurrent liver disease, ciclosporin, tacrolimus, nephrotoxic antibiotics, and radiation nephropathy for acute renal failure. For chronic renal failure, Cohen states that when ciclosporin and tacrolimus nephrotoxic effects have been ruled out, the disorder may be labelled BMT nephropathy, which is a form of radiation nephropathy, related to the total body irradiation used for conditioning.However, Cohen provides no data or comments on chronic progressive renal failure after high-dose ifosfamide. Ifosfamide is frequently used for high-dose conditioning before autologous stem-cell transplantation. Nephrotoxic effects of ifosfamide were first described in 1972. Reversible acute proximal tubular dysfunction is the most common and generally most important feature of toxicity.2Skinner R Pearson AD English MW et al.Risk factors for ifosfamide nephrotoxicity in children.Lancet. 1996; 348: 578-580Summary Full Text Full Text PDF PubMed Scopus (100) Google Scholar Glomerular toxic effects after ifosfamide, leading to chronic renal failure, are not as well recognised as renal tubular damage. However, we and others have reported that severe chronic progressive renal failure might occur after high-dose ifosfamide with or without subsequent autologous stem-cell transplantation.2Skinner R Pearson AD English MW et al.Risk factors for ifosfamide nephrotoxicity in children.Lancet. 1996; 348: 578-580Summary Full Text Full Text PDF PubMed Scopus (100) Google Scholar, 3Krämer A Goldschmidt H Hahn U Andrassy K Progressive renal failure in two breast cancer patients after high-dose ifosfamide.Lancet. 1994; 344: 1569Abstract PubMed Scopus (7) Google Scholar, 4Berns JS Haghighat A Staddon A et al.Severe, irreversible renal failure after ifosfamide treatment: a clinicopathologic report of two patients.Cancer. 1995; 76: 497-500Crossref PubMed Scopus (35) Google Scholar, 5Prasad VK Lewis IJ Aparicio SR et al.Progressive glomerular toxicity of ifosfamide in children.Med Pediatr Oncol. 1996; 27: 149-155Crossref PubMed Scopus (44) Google ScholarIrreversible severe renal failure seems to be caused by nephrotoxic damage of renal tubular epithelium and microvasculature by ifosfamide and, especially, its later onset and progressive nature are major causes for concern. Therefore, nephrotoxic effects from ifosfamide should be considered as a possible cause for acute as well as chronic progressive renal failure after stem-cell transplantation, and renal function should be monitored closely during and after high-dose ifosfamide treatment. In his Jan 6 commentary, Eric Cohen1Cohen EP Renal failure after bone marrow transplantation.Lancet. 2001; 357: 6-7Summary Full Text Full Text PDF PubMed Scopus (60) Google Scholar summarises the causes of acute and chronic renal failure after autologous or allogeneic bone-marrow transplantation (BMT). Specifically, he mentions sepsis due to neutropenia and gastrointestinal exfoliation, hypotension, haemolyticuraemic syndromes, acute tubular necrosis, tumour-lysis syndrome, concurrent liver disease, ciclosporin, tacrolimus, nephrotoxic antibiotics, and radiation nephropathy for acute renal failure. For chronic renal failure, Cohen states that when ciclosporin and tacrolimus nephrotoxic effects have been ruled out, the disorder may be labelled BMT nephropathy, which is a form of radiation nephropathy, related to the total body irradiation used for conditioning. However, Cohen provides no data or comments on chronic progressive renal failure after high-dose ifosfamide. Ifosfamide is frequently used for high-dose conditioning before autologous stem-cell transplantation. Nephrotoxic effects of ifosfamide were first described in 1972. Reversible acute proximal tubular dysfunction is the most common and generally most important feature of toxicity.2Skinner R Pearson AD English MW et al.Risk factors for ifosfamide nephrotoxicity in children.Lancet. 1996; 348: 578-580Summary Full Text Full Text PDF PubMed Scopus (100) Google Scholar Glomerular toxic effects after ifosfamide, leading to chronic renal failure, are not as well recognised as renal tubular damage. However, we and others have reported that severe chronic progressive renal failure might occur after high-dose ifosfamide with or without subsequent autologous stem-cell transplantation.2Skinner R Pearson AD English MW et al.Risk factors for ifosfamide nephrotoxicity in children.Lancet. 1996; 348: 578-580Summary Full Text Full Text PDF PubMed Scopus (100) Google Scholar, 3Krämer A Goldschmidt H Hahn U Andrassy K Progressive renal failure in two breast cancer patients after high-dose ifosfamide.Lancet. 1994; 344: 1569Abstract PubMed Scopus (7) Google Scholar, 4Berns JS Haghighat A Staddon A et al.Severe, irreversible renal failure after ifosfamide treatment: a clinicopathologic report of two patients.Cancer. 1995; 76: 497-500Crossref PubMed Scopus (35) Google Scholar, 5Prasad VK Lewis IJ Aparicio SR et al.Progressive glomerular toxicity of ifosfamide in children.Med Pediatr Oncol. 1996; 27: 149-155Crossref PubMed Scopus (44) Google Scholar Irreversible severe renal failure seems to be caused by nephrotoxic damage of renal tubular epithelium and microvasculature by ifosfamide and, especially, its later onset and progressive nature are major causes for concern. Therefore, nephrotoxic effects from ifosfamide should be considered as a possible cause for acute as well as chronic progressive renal failure after stem-cell transplantation, and renal function should be monitored closely during and after high-dose ifosfamide treatment." @default.
• W2008505946 created "2016-06-24" @default.
• W2008505946 creator A5018685139 @default.
• W2008505946 creator A5067574718 @default.
• W2008505946 creator A5078452627 @default.
• W2008505946 date "2001-07-01" @default.
• W2008505946 modified "2023-09-25" @default.
• W2008505946 title "Renal failure after bone marrow transplantation" @default.
• W2008505946 cites W1975803636 @default.
• W2008505946 cites W1994892212 @default.
• W2008505946 cites W2004724334 @default.
• W2008505946 cites W2059222998 @default.
• W2008505946 cites W2062360461 @default.
• W2008505946 doi "https://doi.org/10.1016/s0140-6736(01)05353-3" @default.
• W2008505946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11469237" @default.
• W2008505946 hasPublicationYear "2001" @default.
• W2008505946 type Work @default.
• W2008505946 sameAs 2008505946 @default.
• W2008505946 citedByCount "2" @default.
• W2008505946 countsByYear W20085059462018 @default.
• W2008505946 crossrefType "journal-article" @default.
• W2008505946 hasAuthorship W2008505946A5018685139 @default.
• W2008505946 hasAuthorship W2008505946A5067574718 @default.
• W2008505946 hasAuthorship W2008505946A5078452627 @default.
• W2008505946 hasBestOaLocation W20085059461 @default.
• W2008505946 hasConcept C126189478 @default.
• W2008505946 hasConcept C126322002 @default.
• W2008505946 hasConcept C134018914 @default.
• W2008505946 hasConcept C2776694085 @default.
• W2008505946 hasConcept C2777063308 @default.
• W2008505946 hasConcept C2778384902 @default.
• W2008505946 hasConcept C2779528694 @default.
• W2008505946 hasConcept C2780091579 @default.
• W2008505946 hasConcept C2781184683 @default.
• W2008505946 hasConcept C2909675724 @default.
• W2008505946 hasConcept C2911091166 @default.
• W2008505946 hasConcept C555293320 @default.
• W2008505946 hasConcept C71924100 @default.
• W2008505946 hasConcept C90924648 @default.
• W2008505946 hasConceptScore W2008505946C126189478 @default.
• W2008505946 hasConceptScore W2008505946C126322002 @default.
• W2008505946 hasConceptScore W2008505946C134018914 @default.
• W2008505946 hasConceptScore W2008505946C2776694085 @default.
• W2008505946 hasConceptScore W2008505946C2777063308 @default.
• W2008505946 hasConceptScore W2008505946C2778384902 @default.
• W2008505946 hasConceptScore W2008505946C2779528694 @default.
• W2008505946 hasConceptScore W2008505946C2780091579 @default.
• W2008505946 hasConceptScore W2008505946C2781184683 @default.
• W2008505946 hasConceptScore W2008505946C2909675724 @default.
• W2008505946 hasConceptScore W2008505946C2911091166 @default.
• W2008505946 hasConceptScore W2008505946C555293320 @default.
• W2008505946 hasConceptScore W2008505946C71924100 @default.
• W2008505946 hasConceptScore W2008505946C90924648 @default.
• W2008505946 hasIssue "9276" @default.
• W2008505946 hasLocation W20085059461 @default.
• W2008505946 hasLocation W20085059462 @default.
• W2008505946 hasOpenAccess W2008505946 @default.
• W2008505946 hasPrimaryLocation W20085059461 @default.
• W2008505946 hasRelatedWork W1975335724 @default.
• W2008505946 hasRelatedWork W2027233144 @default.
• W2008505946 hasRelatedWork W2027488101 @default.
• W2008505946 hasRelatedWork W2074464391 @default.
• W2008505946 hasRelatedWork W2083488586 @default.
• W2008505946 hasRelatedWork W2208852829 @default.
• W2008505946 hasRelatedWork W2209285207 @default.
• W2008505946 hasRelatedWork W2279898714 @default.
• W2008505946 hasRelatedWork W2369973674 @default.
• W2008505946 hasRelatedWork W2615931969 @default.
• W2008505946 hasVolume "358" @default.
• W2008505946 isParatext "false" @default.
• W2008505946 isRetracted "false" @default.
• W2008505946 magId "2008505946" @default.
• W2008505946 workType "article" @default.